Anzeige
Mehr »
Login
Sonntag, 19.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
GOLD-MINEN vor Jahrhundert-Hausse?! Diese Aktie sofort kaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DL9U | ISIN: US30049G2030 | Ticker-Symbol: EV00
Tradegate
16.05.24
16:35 Uhr
0,472 Euro
+0,052
+12,38 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
EVOKE PHARMA INC Chart 1 Jahr
5-Tage-Chart
EVOKE PHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,3900,47019:04
0,4060,43617.05.

Aktuelle News zur EVOKE PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoEvoke Pharma, Inc.: Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference1
MiEvoke Pharma GAAP EPS of -$0.17 beats by $0.04, revenue of $1.73M misses by $0.41M2
DiEvoke Pharma Inc reports results for the quarter ended in January - Earnings Summary-
DiEvoke Pharma Inc - 10-Q, Quarterly Report1
DiEvoke Pharma, Inc.: Evoke Pharma Reports First Quarter 2024 Financial Results97114% year-over-year increase in net product sales70% prescriber growth in Q1 2024 compared to Q4 2023Growing sales metrics reaffirms company's $14M net revenue guidance for 2024 SOLANA BEACH, Calif....
► Artikel lesen
DiEvoke Pharma Inc - 10-K/A, Annual Report1
DiEvoke Pharma Inc - 8-K, Current Report1
17.04.Evoke Pharma, Inc.: Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications5
21.03.Evoke Pharma names Matthew D'Onofrio as new CEO1
21.03.Evoke Pharma, Inc.: Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer421SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
► Artikel lesen
21.03.Evoke Pharma Inc - 8-K, Current Report1
15.03.Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript1
14.03.Evoke Pharma Inc reports results for the quarter ended in December - Earnings Summary1
14.03.Evoke Pharma GAAP EPS of -$0.59 revenue of $1.7M2
14.03.Recap: Evoke Pharma Q4 Earnings2
14.03.Evoke Pharma, Inc.: Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results222Fiscal year 2023 net product sales from prescriptions totaled approximately $5.2M, a 107% increase from 2022 Company projects $14M in net revenue for 2024 SOLANA BEACH, Calif., March 14, 2024 (GLOBE...
► Artikel lesen
14.03.Evoke Pharma Inc - 10-K, Annual Report1
14.03.Evoke Pharma Inc - 8-K, Current Report1
13.03.A Preview Of Evoke Pharma's Earnings2
07.03.Evoke Pharma, Inc.: Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 20241
Seite:  Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1